Skip to main content
. 2011 Feb 12;3(1):47–51. doi: 10.4021/jocmr499w

Table 1. Additional Patients' Information.

Sr. No. 1 2 3 4
Age at Entry 66 51 60 72
RhLF Dose 9 g/day 9 g/day 9 g/day 9 g/day
Histology Clear cell Clear cell Clear, Spindle cell Clear cell
Previous Therapy nephrectomy nephrectomy, IL-2, interferon-α nephrectomy, IL2, interferon-α, methionine restriction nephrectomy, Capecitabine, Gemcitabine, interferon-α, thalidomide
MSKCC Risk Low Low Low Low
Patient Status Alive after 6 years Alive after 5.5 years Alive after 7.5 years Died after 37 months
PFS (Months) 35 50 35 34